CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Sales of GLP-1 products were in-line with consensus ... within Novo's guidance and factoring in the currency tailwind. With cagrisema's obesity filing pushed to the first quarter of 2026 due ...

with combination therapy cagrisema in phase 3 in diabetes and obesity. GLP-1 therapies also have potential in other cardiometabolic and adjacent indications, like heart failure, fatty liver ...

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Competition is tightening, with Eli Lilly (NYSE:LLY) racing alongside Novo in the GLP-1 space. Novo's pipeline powerhouse, CagriSema, recently fell short of its weight-loss goals, but its ...

Competition is tightening, with Eli Lilly (NYSE:LLY) racing alongside Novo in the GLP-1 space. Novo's pipeline powerhouse, CagriSema, recently fell short of its weight-loss goals, but its established ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and development efforts. Since 2023, there has been rapid growth in the market ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...